Business Context and Reporting Period
Company: CalciMedica, Inc. (CALC)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: CalciMedica is a clinical-stage biopharmaceutical company developing therapeutics targeting calcium release-activated calcium (CRAC) channels for serious inflammatory and immunologic illnesses. The company has no approved products and has never generated revenue from product sales. Its lead candidate, Auxora (zegocractin), is being developed for acute pancreatitis (AP), acute kidney injury (AKI), and pediatric asparaginase-induced pancreatic toxicity (AIPT). A second candidate, CM5480, is in preclinical development for pulmonary arterial hypertension (PAH).
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(29.6) million | $(13.7) million |
| Total Operating Expenses | $(23.1) million | $(24.2) million |
| Cash, Cash Equivalents, and Short-Term Investments | $13.0 million | $18.7 million |
| Accumulated Deficit | $(189.3) million | $(159.8) million |
| Debt (Promissory Note) | $9.7 million (Fair Value) | $0 |
| Warrant Liability | $8.0 million | $1.7 million |
Note: The company reported a non-cash loss of $6.0 million in 2025 related to changes in the fair value of financial instruments (warrants and promissory note), compared to a $9.5 million gain in 2024.
Material Changes vs. Prior Period
- Net Loss Increase: Net loss increased by 116% to $29.6 million in 2025 from $13.7 million in 2024. This was primarily driven by a $16.9 million swing in "Other income (expense)" due to fair value adjustments on financial instruments (a $6.0 million loss in 2025 vs. a $9.5 million gain in 2024) and increased interest expense of $1.4 million.
- Operating Expenses: Total operating expenses decreased slightly by 4% to $23.1 million. Research and Development (R&D) expenses increased 5% to $15.2 million, while General and Administrative (G&A) expenses decreased 19% to $7.9 million, largely due to reduced transaction costs and professional fees.
- Debt Financing: In February 2025, the company entered into a Loan Agreement with Avenue Venture Opportunities Fund for up to $32.5 million. The initial $10.0 million tranche was funded in March 2025. However, subsequent tranches are no longer available following the discontinuation of the KOURAGE trial.
- Equity Financing: The company raised approximately $5.6 million in net proceeds through its At-The-Market (ATM) facility during 2025.
Guidance, Outlook, Risks, and Unusual Items
Going Concern Uncertainty
Management has raised substantial doubt about the company's ability to continue as a going concern. As of December 31, 2025, cash and short-term investments totaled $13.0 million. Management estimates these resources will fund operations only into the fourth quarter of 2026. The company will require substantial additional capital to complete development and commercialization.
Clinical Trial Discontinuation (Unusual Item)
In January 2026 (subsequent to the reporting period), the company discontinued the KOURAGE Phase 2 clinical trial for Auxora in patients with AKI and acute hypoxemic respiratory failure (AHRF). This decision followed a recommendation from the Independent Data Monitoring Committee (IDMC) due to a safety concern regarding a mortality imbalance. The IDMC did not identify drug-related toxicity, suggesting baseline disease severity imbalances may have contributed. Consequently, the remaining tranches of the $32.5 million loan facility are no longer available.
Outlook and Strategy
- Acute Pancreatitis (AP): The company plans to finalize the design for a pivotal program in AP in the first half of 2026, subject to funding.
- AKI: The company plans to discuss KOURAGE data and potential future development with the FDA in the second quarter of 2026.
- CM5480 (PAH): IND submission is anticipated in 2027.
Key Risks
- Liquidity: Inability to raise additional capital could force delays or termination of clinical programs.
- Regulatory: No products are approved; regulatory pathways for novel CRAC channel inhibitors are unproven.
- Manufacturing: Reliance on third-party manufacturers, including a single-source supplier in China for active pharmaceutical ingredients (API), creates supply chain risks.
- Intellectual Property: Patents for Auxora expire between 2031 and 2046; protection is subject to legal challenges.
Investor Verification Checklist
- Cash Runway: Verify the specific timeline for cash exhaustion (projected Q4 2026) and the status of any new financing efforts post-filing.
- Loan Covenant Impact: Confirm the specific impact of the KOURAGE trial discontinuation on the $32.5 million loan facility and whether any covenants have been triggered.
- Pivotal Trial Design: Monitor the FDA engagement regarding the pivotal trial design for Acute Pancreatitis expected in H1 2026.
- Supply Chain: Assess the risk mitigation strategies for the single-source API supplier in China, particularly in light of the BIOSECURE Act and potential trade restrictions.
- Warrant Liability Volatility: Review the sensitivity of the $8.0 million warrant liability to stock price fluctuations, as this significantly impacts reported net loss.